IBA, NST combine in molecular imaging pact
This article was originally published in Clinica
Radiopharmaceuticals company Ion Beam Applications (IBA) and Israeli firm NeuroSurvival Technologies (NST) will work together to scale up manufacturing of the latter's Aposense molecular imaging agent and make it available to multi-center clinical trial sites in the US. Aposense targets cells that are undergoing apoptosis, or programmed cell death, a phenomenon associated with many medical disorders. The two firms will first develop the radio-chemistry and processes needed for GMP-grade radio-labelling of Aposense, making it compatible for large scale commercialisation and distribution. IBA (Louvain-la-Neuve, Belgium) and NST will both supply the radio-labelled agent to the clinical trial sites and will negotiate commercial supply terms following FDA approval of the product. Financial terms of the agreement were not revealed.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals